Results of included studies
| Outcome at 2 years | TAP | VIP | ||||
|---|---|---|---|---|---|---|
| PDT | Placebo | RR | PDT | Placebo | RR | |
| n = 402 | n = 207 | (95% CI) | n = 225 | n = 114 | (95% CI) | |
| 95% confidence intervals calculated from data presented in published papers. | ||||||
| *No standard deviation or other measure of spread given, p level as reported in published paper. | ||||||
| Loss of 15 or more letters | 47.0% | 62.3% | 0.75 (0.65 to 0.88) | 53.8% | 66.7% | 0.81 (0.68 to 0.96) |
| Mean number of contrast sensitivity letters lost | 1.3* | 5.2* | Not applicable | Not reported | ||
| p<0.001 for difference | ||||||
| Mortality | 3.2% | 3.9% | 0.84 (0.35 to 2.0) | 1.8% | 2.6% | 0.68 (0.15 to 3.0) |
| Severe visual loss (>20 letters) within 1 week | 0.7% | 0% | 3.6 (0.19 to 70) | 4.4% | 0% | 11 (0.63 to 110) |
| Adverse events associated with treatment | 47.8% | 33.8% | 1.4 (1.1 to 1.8) | 42.7% | 18.4% | 2.3 (1.5 to 3.5) |
| Injection site adverse events | 15.9% | 5.8% | 2.8 (1.5 to 5.0) | 8.0% | 5.3% | 1.5 (0.62 to 3.7) |
| Photo-sensitivity reactions | 3.5% | 0% | 15 (0.9 to 250) | 0.5% | 0.9% | 0.51 (0.03 to 8.0) |